Fibroblast-adapted human CMV vaccines elicit predominantly conventional CD8 T cell responses in humans.
J Exp Med
; 214(7): 1889-1899, 2017 Jul 03.
Article
in En
| MEDLINE
| ID: mdl-28566275
ABSTRACT
Cytomegalovirus (CMV)-based vaccines have shown remarkable efficacy in the rhesus macaque model of acquired immune deficiency syndrome, enabling 50% of vaccinated monkeys to clear a subsequent virulent simian immunodeficiency virus challenge. The protective vaccine elicited unconventional CD8 T cell responses that were entirely restricted by MHC II or the nonclassical MHC I molecule, MHC-E. These unconventional responses were only elicited by a fibroblast-adapted rhesus CMV vector with limited tissue tropism; a repaired vector with normal tropism elicited conventional responses. Testing whether these unusual protective CD8 T responses could be elicited in humans requires vaccinating human subjects with a fibroblast-adapted mutant of human CMV (HCMV). In this study, we describe the CD8 T cell responses of human subjects vaccinated with two fibroblast-adapted HCMV vaccines. Most responses were identified as conventional classically MHC I restricted, and we found no evidence for MHC II or HLA-E restriction. These results indicate that fibroblast adaptation alone is unlikely to explain the unconventional responses observed in macaques.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cytomegalovirus Infections
/
CD8-Positive T-Lymphocytes
/
Cytomegalovirus Vaccines
/
Cytomegalovirus
/
Fibroblasts
Limits:
Humans
/
Male
Language:
En
Journal:
J Exp Med
Year:
2017
Document type:
Article